Publications

A comparison of patient characteristics treated with nivolumab for recurrent/metastatic (r/m) squamous cell carcinoma of the head and neck (SCCHN) in Germany and the USA →

von der Hyde, E, Welslau, M, Gauler, T, Rothni,e K, Waldenberger, D, Deitz, A

November 2019

Abstract

EU ISPOR

Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with frontline BRAF/MEK inhibitors, anti-PD-1, or nivolumab/ipilimumab →

Moser, JC, Chen, D, Hu-Lieskoven, S, Grossman, KF, Patel, SB, Colonna, SV, Ying, J, Hyngstrom, JR

November 2019

Manuscript

Cancer Medicine

Real-world treatment patterns of patients with recurrent/metastatic head and neck squamous cell carcinoma who were eligible for second-line therapy after platinum-based chemotherapy →

Seal, B, Sun, P, Wang, H

October 2019

Abstract

AMCP Nexus

Real-world survival and treatment patterns of patients with recurrent/metastatic head and neck squamous cell carinoma who were eligible for first-line therapy →

Sun, P, Seal, B, Wang, H

October 2019

Abstract

AMCP Nexus

Medicaid expansion and racial inequities in next-generation sequencing testing in oncology

Hooley, IJ, Cohen, AB, Gross, CP, Williams, ER, Adamson, BJS

October 2019

Abstract

Applying Big Data to Address the Social Determinants of Health in Oncology

Flatiron-authored

Technology-enabled clinical trials: Transforming medical evidence generation →

Marquis-Gravel, G, Roe, MT, Turakhia, MP, Boden, W, Temple, R, Sharma, A, Hirshberg, B, Slater, P, Craft, N, Stockbridge, N, McDowell, B, Waldstreicher, J, Bourla, AB, Bansilal, S, Wong, JL, Meunier, C, Kassahun, H, Coran, P, Bataille, L, Patrick-Lake, B, Hirsch, BR, Reites, J, Mehta, R, Muse, ED, Chandross, KJ, Silverstein, JC, Silcox, C, Overhage, JM, Califf, RM, Peterson, ED

October 2019

Manuscript

Circulation

Flatiron-authored

Cancer immunotherapy use and effectiveness in real-world patients living with HIV →

Adamson, BJS, Cohen, AB, Cheever, MA, Hooley, IJ, Williams, ER, Tymejczyk, O, Peeples, M, Hernandez, M, Meropol, NJ, Uldrick, TS

October 2019

Abstract

International Conference on Malignancies in HIV/AIDS

Flatiron-authored

Real-world outcomes associated with the use of companion diagnostics in NSCLC, Flatiron Health 2011-2018 →

John, A.

October 2019

Abstract

Asian Conference on Pharmacoepidemiology

Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma →

Moser, JC, Wei, G, Colonna, SV, Grossman, KF, Patel, SB, Hyngstrom, JR

October 2019

Abstract

ESMO Annual Congress

Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis →

Torres, M, Liu, X, Mardekian, J, McRoy, L

October 2019

Abstract

ESMO Annual Congress

Brain metastases, treatment patterns, and outcomes in ROS1-positive NSCLC patients from US oncology community centers →

Krebs, MG, Perez, L, Surinach, A, Doebele, RC, Martina, R, Martinec, M, Riehl, T, Meropol, NJ, Wong, WB, Crane, G

October 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) →

Cohen, AB, Neri, B, Adamson, BJS, Scanlon, CM, Gross, CP, Meropol, NJ, Miksad, RA

October 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Treatment patterns and outcomes for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice →

Krebs, MG, Polito, L, Smoljanovic, V, Trinh, H, Crane, G

September 2019

Abstract

ESMO Annual Congress

Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices →

Layman, RM, Liu, X, Mardekian, J, McRoy, L

September 2019

Abstract

ESMO Annual Congress

Use of trastuzumab emtansine (T-DM1) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world →

Sanglier, T, Fabi, A, Flores, C, Flahavan, EM, Lindegger, N, Montemurro, F

September 2019

Abstract

ESMO Annual Congress

Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients →

Jiao, X, Lokker, A, Snider, J, Castellanos, EH, Nanda, S, Fisher, V, Zong, J, Keating, K, Fellous, M

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies →

Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset →

Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC) →

Ma, X, Nussbaum, NC, Magee, K, Bourla, AB, Tucker, MG, Bellomo, L, Bennette, CS

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer →

Parikh RB, Adamson BJS, Khozin S, Galsky MD, Baxi SS, Cohen A, Mamtani R

September 2019

Manuscript

JAMA

Flatiron-authored

Real-world treatment patterns and clinical outcomes across lines of therapy in patients with advanced/metastatic gastric or gastroesophageal junction cancer →

Le, DT, Ott, PA, Korytowsky, B, Le, H, Le, TK, Zhang, Y, Maglinte, GA, Abraham, P, Patel, D, Shangguan, T, Chau, I

September 2019

Manuscript

Clinical Colorectal Cancer

Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer →

Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T

September 2019

Manuscript

Gastric Cancer

Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET)

Bartlett, CH, Mardekian, J, Yu-Kite, M, Cotter, MJ, Kim, S, Decembrino, J, Snow, T, Carson, KR, Rockland, JM, Kraus, AL, Wilner, KD, Oharu, N, Schnell, P, Lu, D, Tursi, J

September 2019

Abstract

Annual Metastatic Breast Cancer Conference

Flatiron-authored

Cost effectiveness of PD-L1-based test-and-treat strategy with pembrolizumab as the first-line treatment for metastatic NSCLC in Hong Kong →

Loong HH, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC

September 2019

Manuscript

Pharmacoeconomics Open

Real-world clinical and economic outcomes and the role of bevacizumab in non-small cell lung cancer patients with liver metastases →

Wong, WB, Wu, N, Yang, E, Davies, J, Chae, YK

September 2019

Manuscript

Journal of Oncology Practice

LKB1 mutations in metastatic non-small cell lung cancer (mNSCLC): Prognostic value in the real world →

Golozar, A, Collins, J, Fraeman, K, Nordstrom, BL, McEwen, R, Shire, N, Higgs, B

September 2019

Abstract

World Conference on Lung Cancer

Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR exon 20 insertion mutations →

Dersarkissian, M, Bhak, R, Lin, HM, Li, S, Cheng, M, Lax, A, Huang, H, Duh, MS, Ou, S-H

September 2019

Abstract

World Conference on Lung Cancer

Real-world treatment patterns and outcomes in ALK+ NSCLC patients receiving immuno-oncology therapy in the United States →

Pan, X, Lin, HM, Yin, Y, Cheng, M-R, Baumann, P, Jahanzeb, M

September 2019

Abstract

World Conference on Lung Cancer

Pembrolizumab for previously treated PD-L1-expressing advanced NSCLC: Real-world time on treatment and overall survival →

Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T

September 2019

Abstract

World Conference on Lung Cancer

Real-world trends in systemic therapy for nonsquamous EGFR/ALK-negative advanced NSCLC (aNSCLC) in the U.S., 2011-2018 →

Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T

September 2019

Abstract

World Conference on Lung Cancer

Temporal trends in treatment patterns for advanced/metastatic non-small cell lung cancer (aNSCLC) in routine clinical practice →

Stefaniak, VJ, Winfree, KB, Molife, C

September 2019

Abstract

World Conference on Lung Cancer

New treatment option for ES-SCLC: Patient characteristics and use of an atezolizumab regimen in the real-world setting →

McCune, S, Ton, TGN, Whipple, S, Induru, RR, Horn, L, Percent, IJ, Mekhail, T, Goldschmidt, Jr., J, Leal, TA, MacVicar, GR, Braiteh, F, Daniel, DB, Hussein, M, Mansfield, AS, Lam, S, Johnson, A, Morris, S, Spira, A

September 2019

Abstract

World Conference on Lung Cancer

Rates of systemic anticancer therapy (SACT) for advanced non-small cell lung cancer (aNSCLC) in the U.S. 2011-2018. →

Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T

September 2019

Abstract

World Conference on Lung Cancer

Lung cancer prognostic index performance in U.S. real-world advanced non-small cell lung cancer patients →

Shah, RA, John, A, Alexander, M

September 2019

Abstract

World Conference on Lung Cancer

Real-world trends in systemic anticancer therapy (SACT) for squamous advanced NSCLC (aNSCLC) in the U.S. 2011-2018 →

Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T

September 2019

Abstract

World Conference on Lung Cancer

BRAF mutations are associated with increased benefit from PD-1/PD-L1 blockade compared with other oncogenic drivers in non-small cell lung cancer →

Heymach, JV, Shames, DS, Albacker, LA, Frampton, GM, Alexander, BM, Miller, VA, Glisson, BS, Gibbons, DL, Papadimitrakopoulou, V, Tsao, AS, Lee, J, Swisher, S, Roth, JA, Simon, GS, Rinsurongkawong, W, Barreto, D, Zhang, J, Wu, C-J, Goldberg, ME, Le, X, Elamin, Y, Hu, S, Shen, V, Bara, I, Schulze, K, Montesion, M, Skoulidis, F, Negrão, M

September 2019

Abstract

World Conference on Lung Cancer

Real-world outcomes of advanced NSCLC patients with common and uncommon/complex EGFR mutation profiles →

Riely, GJ, Lovly, CM, Messina, CGM, Bienert, S, Alexander, K, Pao, W, Magee, K, Baxi, SS, Doebele, RC

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Real-world survival of relapsed compared to de-novo stage IV diagnosis of advanced non-small cell lung cancer →

Kerrigan, KC, Halland, B, Adamson, BJS, Patel, SB, Akerley, WL

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Real-world characterization of advanced non-small cell lung cancer in never smokers →

Kerrigan, KC, Halland, B, Adamson, BJS, Patel, SB, Akerley, WL

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Retrospective analysis of real-world clinico-genomic data for clinical impact of genomic profiling of CTDNA in NSCLC →

Madison, R, Schrock, AB, Gregg, JP, Carson, KR, Castellanos, EH, Singal, G, Miller, VA, Ali, SM, Alexander, BM, Chung, JH

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients →

Doebele, RC, Perez, L, Trinh, H, Martinec, M, Martina, R, Riehl, T, Krebs, MG, Meropol, NJ, Wong, WB, Crane, G

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Development of a time to treatment metric across an NCI designated academic health system →

Najarian, ML, Shaw, P, Severino, KM, Hamrick, HJ, Adelson, KB, Miksad, RA

September 2019

Abstract

ASCO Quality Care Symposium

Flatiron-authored

Treatment pattern and real-world effectiveness on non-small cell lung cancer patients harboring major single and double EGFR mutations →

So, WV, Yang, X, Leddin, M, Chen, L, Nagel, YA

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Deep learning-based propensity score computation: Cohort study in second line treated advanced non-small cell lung cancer (aNSCLC) patients →

Weberpals, J, Becker, T, Schmich, F, Rüttinger, D, Theis, FJ, Bauer-Mehren, A

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Metastatic breast cancer sub-type classification using biomarker and treatment information in electronic health records →

Craggs, C, Flahavan, EM, Surinach, A, Kent, M, Sanglier, T

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Validation of an algorithm to predict treatment discontinuation status in electronic health records →

Davies, J, Sanglier, T, Shim, J, Hibbert, A, Taylor, MD, Carson, KR

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

Validation of diagnosis codes to identify side of colon in an electronic health record registry →

Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R, Tucker MG, Arnieri B, Taylor MD, Meropol NJ

August 2019

Manuscript

BMC Medical Research Methodology

Flatiron-authored

Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non–small-cell lung cancer data set →

Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams E, George DJ, Schrag D, Khozin S, Capra WB, Taylor MD, Abernethy AP

August 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer →

Luhn P, Chui SY, Hsieh AF, Yi J, Mecke A, Bajaj PS, Hasnain W, Falgas A, Ton TG, Kurian AW

August 2019

Manuscript

Journal of Comparative Effectiveness Research

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer →

Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, Kaganman I, Kuk D, Rockland JM, Pazdur R, Torres AZ, Zhi J, Abernethy AP

August 2019

Manuscript

Cancer

Flatiron-authored